Metraipolis › archive › dc_ade12446773f

Nationwide Survival Impact of Bevacizumab Under National Reimbursement for Advanced Cervical Cancer in South Korea — Europe PMC PMID:41595264

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41595264
DOI
10.3390/cancers18020346
License (as archived)
solo-consultazione
Archived
2026-11-06T13:45:01.139Z
SHA-256 of the archived text
5245a3c60eb70d5abf968c505fc208eb340dbb6c1ff774b8696abe618fa2ea4a
Stable URL of this page
https://metraipolis.com/documento/dc_ade12446773f

How to cite

Nationwide Survival Impact of Bevacizumab Under National Reimbursement for Advanced Cervical Cancer in South Korea — Europe PMC PMID:41595264 — Europe PMC (en), https://europepmc.org/article/MED/41595264 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ade12446773f (Metraipolis archive dc_ade12446773f, sha256 5245a3c60eb70d5abf968c505fc208eb340dbb6c1ff774b8696abe618fa2ea4a)
BibTeX
@misc{dcade12446773f,
  title = {Nationwide Survival Impact of Bevacizumab Under National Reimbursement for Advanced Cervical Cancer in South Korea — Europe PMC PMID:41595264},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41595264},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ade12446773f; sha256 5245a3c60eb70d5abf968c505fc208eb340dbb6c1ff774b8696abe618fa2ea4a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41595264. Agents can read the archived copy with the MCP tool read_document.